We detected syndecan-4 copy-number amplification in 28% of FNRMS cases accompanied by high levels of syndecan-4 expression suggesting that syndecan-4 can serve as a tumor driver gene in promoting rabdomyosarcoma development. This evidence concerns the gene SDC4 and neoplasm.